11月11日 - 歌礼制药-B(01672.HK):该公司已向美国FDA递交ASC30_39 FDC的临床试验申请。该药物是一种潜在首创的口服小分子固定剂量复方制剂,由GLP-1R激动剂与选择性胰淀素受体激动剂组成,拟用于治疗肥胖症。
11月11日 - 歌礼制药-B(01672.HK):该公司已向美国FDA递交ASC30_39 FDC的临床试验申请。该药物是一种潜在首创的口服小分子固定剂量复方制剂,由GLP-1R激动剂与选择性胰淀素受体激动剂组成,拟用于治疗肥胖症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.